Danish Renewable Energy Stock News

FLSmidth stock came into this earnings print on a strong run, up about 16% over the past month and modestly higher over three months, which indicates sentiment was already warm. The headline today is clear: the market got a capital goods company with real operating traction, not just a story. Order intake in key service and mining pump lines grew at double digit organic rates, and the adjusted earnings before interest, tax and amortisation margin landed at 17.3%. That is a quality...

Jyske Bank stock closed at DKK1,040 today, roughly flat over the past week after a strong 3 month run, and that calm surface hides a sharper earnings story. The headline is simple. The bank printed one of its strongest profit runs in recent years with trailing net income of DKK4,943m and a net margin of 34.9%, while the market still values it on a 12x P/E and a sizeable discount to a DCF based fair value estimate. Emotion looks muted; the numbers suggest a more confident mood. If you like...

Coloplast stock closed at DKK441.8 on Wednesday, only modestly higher over the past week and month, even after investors digested a quarter that quietly reset the earnings narrative. The headline is a sharp profit rebound. Q3 basic earnings per share landed at 6.49 DKK with net income of DKK1,462m and total revenue of DKK7,355m. The market still carries the scar of the recent one off loss that dragged the trailing net margin down to 7.5%. Today’s calm price action suggests investors are...

Novo Nordisk (CPSE:NOVO B) is back in focus after its CEO argued that investors may be undervaluing the long term potential of obesity treatments, along with fresh signals on the company’s shareholder return plans. See our latest analysis for Novo Nordisk. Novo Nordisk’s recent CEO comments and ongoing buyback and dividend plans come after a mixed run, with the share price up 2.76% over 90 days but down 10.17% over 30 days and the 1 year total shareholder return declining 10.80%, while the 3...

Coloplast (CPSE:COLO B) is in focus after third quarter earnings, which showed organic revenue and EBIT growth and a reaffirmed full year outlook, despite ongoing reimbursement pressure in the Biologics segment. See our latest analysis for Coloplast. At a share price of DKK435.6, Coloplast has seen a 3.0% 1 day share price return and a 5.8% 90 day share price return, while the 5 year total shareholder return is down 54.4%. This suggests that recent momentum has improved compared with a weaker...

The market walked into Brødrene A & O Johansen’s Q2 release already leaning positive, with the stock up about 8% over the past month and closing at DKK98.8 just after the numbers dropped. The headline was clear. This was a revenue and earnings beat built on record quarterly sales and fatter margins, not a one off accounting quirk. The emotional tug of the day is whether traders focus on the solid 11.6% revenue growth and stronger EBITDA or worry about rising investment costs and acquisition...

Royal Unibrew stock has slipped over the past week and month, yet today’s earnings story is less gloomy than the recent price action suggests. The brewer delivered Q2 revenue of DKK 4,426m and basic earnings per share of DKK 11.1, with trailing earnings putting the stock on a P/E of 13x, below both peers and the wider European beverage group. The real tension for investors is between that value label and a business still nudged by modest growth and higher debt, which sets the stage for a...

Trifork Group stock has been under quiet pressure, down about 9% over the past week even before investors fully processed fresh Q2 numbers. The headline is not revenue, which came in at €58.356m. The real story is profit. Net income for the quarter was just €0.178m and basic earnings per share slipped to €0.01. That kind of margin squeeze jars with a company trading on a higher P/E than peers and with upbeat multi year growth forecasts on the table. Love Trifork Group's revenue scale but...

Why Genmab’s latest earnings and guidance update matters for investors Genmab (CPSE:GMAB) reported second quarter 2026 results with higher sales but lower net income compared with a year earlier. The company also raised full year revenue guidance, giving investors an updated view of expected performance. See our latest analysis for Genmab. Genmab’s latest earnings release and raised revenue guidance have coincided with strong recent momentum, with a 30 day share price return of 12.57% and a...

Ringkjøbing Landbobank (CPSE:RILBA) has drawn fresh attention after reporting half year 2026 results and raising its full year net profit guidance, citing stronger total income, solid credit quality and lower than budgeted losses. See our latest analysis for Ringkjøbing Landbobank. The earnings update and guidance hike appear to have supported positive momentum in Ringkjøbing Landbobank, with a 90 day share price return of 14.83% and a year to date share price return of 15.87%, while the 5...

As the European markets navigate a landscape marked by resilient economic data and geopolitical uncertainties, investors are increasingly looking towards diverse opportunities. Penny stocks, though an older term, continue to attract attention due to their potential for growth at lower price points. These smaller or newer companies can offer unique investment opportunities when backed by strong financials and solid fundamentals.

As European markets navigate a landscape marked by resilient economic data and geopolitical uncertainties, the pan-European STOXX Europe 600 Index recently experienced a slight downturn of 0.36%. Against this backdrop, dividend stocks can offer investors a source of income stability, particularly when they exhibit strong fundamentals and consistent payout histories.

Netcompany Group A/S ( CPH:NETC ) came out with its half-yearly results last week, and we wanted to see how the...

A week ago, Zealand Pharma A/S ( CPH:ZEAL ) came out with a strong set of second-quarter numbers that could potentially...

Jeudan earnings event puts focus on revenue and profit trends Jeudan (CPSE:JDAN) reported second quarter 2026 results that showed higher sales but lower net income and earnings per share compared with the same period in 2025. Investors now have fresh numbers to reassess the stock. See our latest analysis for Jeudan. Jeudan's latest earnings update comes as the stock trades at DKK204.0, with a 1-day share price return of 0.99% and a year-to-date share price gain of 3.55%. Over the same period,...

ChemoMetec (CPSE:CHEMM) drew fresh investor attention after confirming a collaboration agreement with Roche Diagnostics to link ChemoMetec’s Xcytomatic 30 cell counter to Roche’s Cedex Bio Analyzer through a dedicated hardware and software connection kit. See our latest analysis for ChemoMetec. The Roche collaboration lands at a time when ChemoMetec’s share price shows mixed signals, with a 90 day share price return of 43.79% and a year to date share price return that is down 30.97%, while...

SJF Bank (CPSE:SJF) released half year results to June 30, 2026, reporting net income of DKK 326 million compared with DKK 321.64 million a year earlier, giving investors fresh data on recent performance. See our latest analysis for SJF Bank. The half year figures come at a time when SJF Bank’s share price has gained 27.67% over three months and 14.59% year to date. The 1 year total shareholder return of 33.11% points to momentum that has been building over several years, with a 5 year total...

How NKT’s latest earnings and guidance update set the stage NKT (CPSE:NKT) reported second quarter 2026 earnings that were close to the prior year, alongside six month figures that showed similar stability in sales and net income. On the same day, the company also narrowed its 2026 revenue outlook to a range of €2.65b to €2.75b, compared with earlier guidance of €2.63b to €2.78b. This gave investors a more focused view of expected activity levels for the rest of the year. See our latest...

As the European market navigates a landscape marked by resilient economic data and geopolitical uncertainties, the STOXX Europe 600 Index recently closed slightly lower, reflecting investor caution amid these mixed signals. Despite these challenges, opportunities may exist for investors seeking undervalued stocks that could benefit from current sector shifts and regional economic resilience. In this context, identifying stocks trading below their estimated value can be particularly appealing...

A.P. Møller - Mærsk A/S ( CPH:MAERSK B ) just released its quarterly report and things are looking bullish. A.P. Møller...

Shareholders of DFDS A/S ( CPH:DFDS ) will be pleased this week, given that the stock price is up 19% to kr.155...

It's been a good week for NKT A/S ( CPH:NKT ) shareholders, because the company has just released its latest half-year...

It's been a good week for Solar A/S ( CPH:SOLAR B ) shareholders, because the company has just released its latest...

Aktieselskabet Schouw went into this report with the stock at DKK680 after a solid run over the past month, and the market is now weighing whether that optimism matches the earnings reality. The headline is clear: Q2 2026 delivered a sharp jump in profitability, with basic earnings per share at DKK14.18 and net income at DKK321m, both well ahead of Q1. In addition, management lifted full year revenue and EBITDA guidance for 2026, which puts the focus firmly on whether this improvement looks...